Genetic Engineering (Genetics Podcast 2 of 3)
Mrs. Inabinet describes genetic engineering.From:MrsInabinetViews:0 0ratingsTime:14:56More inEducation

Read this article:
Genetic Engineering (Genetics Podcast 2 of 3) - Video

Recommendation and review posted by Bethany Smith

Far Cry 3 Live Action Trailer (VAAS STORY)
Far Cry 3 is an open world first-person shooter set on a tropical island unlike any other. This is a place where heavily armed warlords traffic in slaves. Where outsiders are hunted for ransom. And as you embark on desperate quest to rescue your friends, you realize that the only way to escape this darkness... is to embrace it. Far Cry 3 releases December 4th on Xbox 360, PlayStation 3, and PC. For more information go to http://www.farcrygame.com. -- Story of the franchise: Far Cry is a first-person shooter video game developed by Crytek Studios and published by Ubisoft on March 23, 2004, for Microsoft Windows. Far Cry sold 730000 units within four months of release.[1] It received positive reviews upon release. The original game has since spawned a series of sequels and spin-off games and a movie. The game #39;s story follows a former US Army Special Forces operative Jack Carver, who is stranded on a mysterious archipelago. He is searching for a female journalist he was escorting after she went missing when their boat was destroyed by mercenaries. The game includes thematic elements relating to the dangers of weaponizing genetic engineering and the genocide of local islanders as can be seen by the deformed creatures created by a mad scientist named Krieger. The terrain in Far Cry varies greatly. Set on a South Pacific archipelago, the landscape includes beaches, dense rain forests, towering canyons, mines, swamps, and even volcanic forests. Many of the interiors range from simple ...From:Michael MyersViews:0 0ratingsTime:02:40More inFilm Animation

Read more here:
Far Cry 3 Live Action Trailer (VAAS STORY) - Video

Recommendation and review posted by Bethany Smith

On the wish lists of Americans: A fully operational Death Star, a nationalized Twinkie industry, and motorcycle-riding "judges" who also act as jury and executioner

The White House's "We the People..." website allows Americans to petition the Obama administration on a variety of issues citizens believe need addressing. Requests range from serious (petition to have the White House publicly acknowledge the U.S. drone program) to self-interested (federally legalize weed now!) to completely absurd (have Vice-President Joe Biden serve asGuy Fieri's sidekick on Diners, Drive-ins, and Dives). Most are angry with the administration, with roughly 70 percent of current petitions asking that individual states like Texas be allowed to peacefully secede. What's more: Anyone can create a petition, with the caveat that each request must garner 25,000 signatures in order to be considered for an official White House response. Presented without comment (and in no particular order), here are 11 of the most ridiculous White House petitions awaiting signatures:

1. Secure resources and funding, and begin construction of a Death Star by 2016

SEE MORE: Obama's second term: The case for implementing health care reform

Those who sign here petition the United States government to secure funding and resources, and begin construction on a Death Star by 2016.

By focusing our defense resources into a space-superiority platform and weapon system such as a Death Star, the government can spur job creation in the fields of construction, engineering, space exploration, and more, and strengthen our national defense.

SEE MORE: Will Republicans abandon their opposition to Susan Rice?

2. Allow United States military service members to place their hands in their pockets

When in the course of human events, it becomes necessary for one people to dissolve the bonds of service to the United States military, this regretful termination of service to this great nation is often precipitated by inane uniform and personal conduct policies.

We hold these truths to be self-evident: that all uniforms have pockets and hands fit perfectly inside them, and they sheathe our knife hands gloriously. It must be acknowledged that placing one's hands in one's pockets is not a sign of disrespect, but a precautionary action to prevent injuries.

View post:
11 ridiculous White House petitions

Recommendation and review posted by Bethany Smith

Public release date: 4-Dec-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, December 4, 2012Human mesenchymal stem cells (hMSCs) can develop into bone cells and are useful for tissue engineering and regeneration. However, when grown in the laboratory they quickly lose their ability to continue dividing and they die. A method for genetically engineering hMSCs so they become immortal and still retain their ability to become bone cells is described in an article published in BioResearch Open Access, a bimonthly peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website at http://www.liebertpub.com/biores.

D.S. Bischoff, N.S. Makhigani, and D.T. Yamaguchi, Veterans Administration Greater Los Angeles Healthcare System and The David Geffen School of Medicine at University of California, Los Angeles, inserted a gene called human telomerase (TERT) into hMSCs. The authors provide evidence to support the ability of human TERT to enhance the growth capacity of hMSCs in "Constitutive Expression of Human Telomerase Enhances the Proliferation Potential of Human Mesenchymal Stem Cells." They demonstrate that they were able to produce a stable hMSC cell line that can be grown in culture through repeated cell divisions and that the stem cells can differentiate into osteoblasts for potential use in bone engineering applications.

"Generating a stable human mesenchymal stem cell line that retains osteoblastic and adipogenic potential has important benefits for bone engineering studies, particularly those which require a large number of cells," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website at http://www.liebertpub.com/biores.

About the Publisher

Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Read more from the original source:
New method for creating long-lived stem cells used for bone replacement

Recommendation and review posted by Bethany Smith

Public release date: 4-Dec-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, December 4, 2012About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

The study, "Osteoporosis Health Care Disparities in Postmenopausal Women," compared referral rates for and the results of bone mineral density screening with dual-energy X-ray absorptiometry (DXA) scans and medication prescribing for women found to have low bone mineral density.

Irene Hamrick, MD, University of Wisconsin, Madison, Qing Cao, MD and Doyle Cummings PharmD, East Carolina University, and Dorothy Agbafe-Mosley, MD, Wilmington, NC, reported that only about a third of eligible women in the study, who were 60 years of age or older and seen in a primary care practice, completed DXA scan screening to determine their osteoporosis risk.

"The results of this study indicate that new strategies are needed to improve rates of screening and treatment for osteoporosis in primary care settings, especially for African American women," says Editor-in-Chief Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the Official Journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

Read more:
Are there racial disparities in osteoporosis screening and treatment?

Recommendation and review posted by Bethany Smith

igsp headline news Published by KENDALL MORGANThursday, November 29, 2012

An all-new edition of Genomic and Personalized Medicine promises to be a one-stop shop for doctors and other health professionals as they face the rapid growth of genetic and genomic testing in the clinic. The comprehensive resource volumes edited by the Duke Institute for Genomes Sciences & Policy's Geoffrey Ginsburg and Huntington Willard are one solution to an increasingly obvious problem: the healthcare workforce on the whole lacks the background to make personalized medicine a reality for patients.

The two-volume set is now available for purchase from Elsevier and Amazon.com as either a hard copy or Kindle Edition. The books can also be purchased electronically in whole or as individual chapters (for just over $30 a piece) from Science Direct, with institutional bulk rates available.

"These books directly connect to our goal of making the genome relevant to our patients and to society," Ginsburg said. "We took this project on because we saw a need to pull together all these bits of fragmented genomic information that could have a bearing on health and healthcare and put them in one place. There is nothing else like it."

The first book in the two-volume set covers everything from essential genome technologies and approaches to their ethical and societal implications and their translation to personalized medicine in the clinic. The second volume presents the latest developments in disease-based genomic and personalized medicine, with sections dedicated to cardiovascular disease, cancer, metabolic disease, mental health, and infectious disease. It's a soup-to-nuts resource intended for specialists in all medical disciplines, for research professionals, and for medical and graduate students alike.

"Once again, Ginsburg and Willard have recruited an impressive cast of geneticists and genomicists to contribute chapters spanning a wide spectrum of topics from fundamentals in genomics research to key clinical areas that represent some of the 'lowest hanging fruit' in terms of opportunities to have genomics change medical practice," writes Director of the National Human Genome Research Institute Eric Green in the foreword. "Together, these chapters provide unequivocal evidence about the current state of genomic and personalized medicine that the opportunities are breathtaking, that the challenges are immense, and that the potential to improve health is nearly unlimited."

"This is the definitive textbook providing the content for a new era of medicine - an era where disease is defined at the molecular level rather than the anatomic level; where therapies are individualized and targeted rather than uniformly applied across a population," said Dietrich Stephan, President and CEO of Silicon Valley Biosystems and Co-Founder of Navigenics. "We have an opportunity with this text to improve patient outcomes using new tools and strategies, which is certainly an exciting prospect for each of us. This text should be mandatory reading for every physician, or physician in training."

Genomic and Personalized Medicine By the Numbers

2 Volumes 164 Contributors 1306 Pages 101 Chapters 63 New Chapters 245 Figures 49 Tables

Read more from the original source:
New Book on Genome and Personalized Medicine Preps Doctors for Changing Reality

Recommendation and review posted by Bethany Smith

SAN DIEGO, CA--(Marketwire - Dec 4, 2012) - Invivoscribe Technologies, Inc., a privately-held life science company based in San Diego, California, announces the launch of Genection, Inc.

Genection provides physicians with a dedicated online platform for global access to the entire clinically-actionable genetic test menu, including both routine and esoteric genetic tests, exome and whole genome sequencing, cancer somatic mutation testing, and pharmacogenomics.

Genection's model is not payor driven, so prescribing physicians have access to genetic tests that may currently be unavailable, overlooked, or even inaccessible through their patients' managed care plans and health care institutions. Combine this comprehensive genetic test offering with convenient online ordering, seamless linking of multiple CLIA and CAP accredited laboratories for reporting and interpretation and integrated service offerings such as next generation sequencing and advanced bioinformatics in a singular location and Genection is streamlining the entire diagnostic pipeline.

"Genection is a valuable tool in the personalized molecular medicine landscape. Clinicians spend too much of their time identifying and ordering clinically relevant genetic tests, while struggling to keep abreast of the flood of clinical information around new biomarkers," said Bradley Patay, M.D., Genection's Chief Medical Officer. "In addition to thebroad selectionof genetic tests available to order through their service, Genection offers one of the most relevant new genomic testing servicesnext generation sequencing used to detect driver mutations in cancer."Oncologists appreciate that current more effective and individualized cancer treatment programs require improved diagnostic stratification of their patients. Using targeted gene assays for deep sequencing of oncogenes and tumor suppressor genes, and exome sequencing to identify rare or unknown genes that may contribute to an individual's cancer, an oncologist can better identify the underlying cause of a patient's tumor to create a more targeted treatment plan.

Genection has agreements in place with several top CLIA and CAP accredited laboratories as well as sequencing centers."Our initial partners include ARUP Laboratories, Foundation Medicine, Cypher Genomics, the Laboratory for Personalized Molecular Medicine (LabPMM) in the U.S., as well as its ISO15189 compliant laboratory (LabPMM GmbH) in Martinsried, Germany," said Suzanne Graham, Genection's Senior Manager of Business Development. "Genection also has established relationships with sequencing providers, including Illumina and Ambry Genetics." Moreover, Genection has alliances with a consortium of genetic counselors, to provide current informed decision making support, reducing costs of the informed consent process, and helping to avoid unnecessary testing.

What does this integration mean for a physician and their patient?

"In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of healthcare.Genection's mission seeks to accelerate this adoption process," Dr. Patay continued. "The combination of CLIA-validated genetic testing, whole exome or whole genome sequencing and broad targeted assays, along with critical bioinformatics, analytic tools, and interpretative guidelines will contribute to timely definitive diagnoses for patients with rare, unexplained diseases or complex diseases; in essence, this integration will speed delivery of genomic test results and improve patient care."

More than just facilitating ordering and transmitting patient reports and data, Genection's service is designed to vastly improve the communication between genetic counselors, physicians and patients. The Genection web application provides HIPAA compliant, secure patient data management for physicians and health organizations. As patient care moves to more team-based management, it is vital for patient information to integrate with several clinicians, and not be limited to one single provider.Genection streamlines this process, allowing clinicians to share test results and genetic information with other healthcare providers, which can assist in a diagnosis for a patient and accelerate creation of individualized treatment plans and potentially life-saving therapies.

Genection also serves as the gateway for the global Together We Cure initiative, which allows acute myeloid leukemia (AML) patients and physicians to share clinical information to facilitate more rapid development of AML targeted therapeutics.

Genection is a privately held company owned by Invivoscribe Technologies, Inc., founded 18 years ago by its Chairman & CEO, Jeffrey E. Miller, Ph.D.Dr. Miller will serve as President of Genection.Bradley A. Patay, MD is Genection's Chief Medical Officer, and Suzanne M. Graham, Ph.D., is Senior Manager of Business Development.

Original post:
Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire ...

Recommendation and review posted by Bethany Smith

NEW YORK (GenomeWeb News) A personalized molecular medicine company offering physicians access to clinically actionable genetic tests has been launched.

The company called Genection was launched today by its owner, molecular diagnostics firm Invivoscribe Technologies. Genection offers both routine and esoteric genetic tests, exome and whole-genome sequencing, cancer somatic mutation testing, and pharmacogenomics.

Because the Genection model is not payor-driven, it said, it can provide doctors access to genetic tests that are currently unavailable, overlooked, or inaccessible through their patients' health plans and healthcare institutions.

The privately held company added that it has agreements in place with several CLIA- and CAP-certified laboratories, including ARUP Laboratories, Foundation Medicine, Cypher Genomics, Invivoscribe's wholly owned subsidiary the Laboratory for Personalized Molecular Medicine and LPMM's laboratory in Martinsried, Germany. It also has relationships with Illumina and Ambry Genetics and agreements with "a consortium" of genetic counselors.

"In order to make personalized molecular medicine a clinical reality, new platforms need to be developed for the delivery of healthcare. Genection's mission seeks to accelerate this adoption process," Genection Chief Medical Officer Bradley Patay said in a statement. "The combination of CLIA-validated genetic testing, whole-exome or whole-genome sequencing, and broad targeted assays, along with critical bioinformatics, analytic tools, and interpretative guidelines will contribute to timely definitive diagnoses for patients with rare, unexplained diseases or complex diseases; in essence, this integration will speed delivery of genomic test results and improve patient care."

The San Diego-based company will serve as the gateway to the Together We Cure, a global initiative aimed at developing treatments for acute myeloid leukemia by facilitating the sharing of clinical information by AML patients and clinicians.

Continued here:
Personalized Molecular Medicine Firm Genection Launched

Recommendation and review posted by Bethany Smith

AS Guru Genetics part 2
The Cell Cycle 70:47From:Nicola BowkerViews:0 0ratingsTime:15:09More inEducation

Read this article:
AS Guru Genetics part 2 - Video

Recommendation and review posted by Bethany Smith

AS Guru Genetics part 3
Protein Synthesis 85:53 Gene technology 94:51From:Nicola BowkerViews:0 0ratingsTime:30:43More inEducation

See the article here:
AS Guru Genetics part 3 - Video

Recommendation and review posted by Bethany Smith

Dr. Sheldon Peck (4 of 7)
Part 4: Main topic part one: "To find clues recorded long before the genetics revolution about abnormal conditions we would know now as familial" Dr. Sheldon Peck (DDS 1966): "The Modern Value of Early Writing in Medicine and Dentistry." Presented by the UNC Health Sciences Library and the Bullitt History of Medicine Club, November 13, 2012.From:hsluncViews:0 0ratingsTime:08:58More inEducation

Visit link:
Dr. Sheldon Peck (4 of 7) - Video

Recommendation and review posted by Bethany Smith

Fuchs Dystrophy - Mayo Clinic
Ophthalmologist Keith Baratz, MD, of Mayo Clinic in Rochester, Minnesota, discusses his work: Fuchs Dystrophy, endothelial keratoplasty and corresponding genetics research.From:mayoclinicViews:3 0ratingsTime:11:04More inScience Technology

Continued here:
Fuchs Dystrophy - Mayo Clinic - Video

Recommendation and review posted by Bethany Smith

Gender Genetics
Learn how you inherited genes to determine if you were born a boy or girl. Men contain sex chromosomes XY and women have sex chromosomes XX.From:Mark DrollingerViews:0 0ratingsTime:03:00More inEducation

View post:
Gender Genetics - Video

Recommendation and review posted by Bethany Smith

Reserva Privada #39;s Kandy Kush and OG Kush Seedlings
Just showing off the new strains the just got added to the garden, kandy kush and og kush. Both strains used the og kush reversal pollen to create the feminized seeds, I #39;ve had so much luck with strains created with those genetics that I wanted to check a few new strains for good pheno types. Like comment subscribe! By the way, I do not own the music playing in the background, fair use! 🙂 Song is Kid Cudi - I Be HighFrom:Theo M.Views:2 2ratingsTime:03:57More inEducation

See original here:
Reserva Privada's Kandy Kush and OG Kush Seedlings - Video

Recommendation and review posted by Bethany Smith

Fragile X at Boston Children #39;s Hospital: What should I expect?
A patient-friendly, behaviorally sensitive guide for children with Fragile X syndrome who are coming to Boston Children #39;s Hospital. It walks children through the entire experience, from arrival at the hospital to visiting Occupational Therapy, Genetics, a pediatrician and a psychologist.From:ChildrensHospitalViews:1 0ratingsTime:06:43More inNonprofits Activism

See the original post:
Fragile X at Boston Children's Hospital: What should I expect? - Video

Recommendation and review posted by Bethany Smith

"Ask the Experts - Living with ALS" Seminar at Cedars-Sinai Medical Center
On Saturday, November 17, 2012, world-renowned researchers involved in the study of ALS participated in a this special event, "Ask the Experts -- Living with ALS" at Cedars-Sinai Medical Center in Los Angeles, California. The event, hosted by The ALS Association Golden West Chapter, offered people with ALS and their loved ones an opportunity to ask their questions directly to scientists and clinicians. Speakers include Catherine Lomen-Hoerth, MD, Ph.D., Director, The ALS Center at UCSF, who will discuss multidisciplinary care and ALS along with The ALS Association #39;s Chief Scientist, Lucie Bruijn, Ph.D., who will present an overview of ALS research. Following these discussions, Robert H. Baloh, MD, Ph.D., Director, Cedars-Sinai ALS Center, Don W. Cleveland, Ph.D, Department Chair, UCSD, and Clive Svendsen, Ph.D., Director, Cedars-Sinai RMI and Chair of the California ALS Research Network will speak about topics such as clinical trials, genetics, and stem cell research. To find out more, please visit: http://www.alsagoldenwest.org or httpFrom:Calabasas3Views:7 0ratingsTime:02:57:25More inEducation

Read more here:
"Ask the Experts - Living with ALS" Seminar at Cedars-Sinai Medical Center - Video

Recommendation and review posted by Bethany Smith

Public release date: 4-Dec-2012 [ | E-mail | Share ]

Contact: Phyllis Edelman pedelman@genetics-gsa.org 301-634-7302 Genetics Society of America

Bethesda, MDDecember 4, 2012 Listed below are the selected highlights for the December 2012 issue of the Genetics Society of America's journal, Genetics. The December issue is available online at http://www.genetics.org/content/current. Please credit Genetics, Vol. 192, December 2012, Copyright 2012.

Please feel free to forward to colleagues who may be interested in these articles.

ISSUE HIGHLIGHTS

Genetic variation in Saccharomyces cerevisiae: Circuit diversification in a signal transduction network, pp. 1523-1532 Brian L. Chin, Owen Ryan, Fran Lewitter, Charles Boone, and Gerald R. Fink The plummeting cost of genome sequencing has revealed increasing amounts of genetic variation within a species. How much of that variation affects function, and how might it help us understand evolution? The authors addressed these questions by looking at how cell adhesion is controlled in two closely related yeast strains. Despite their similar genomic sequences, these two strains use different sets of genes to regulate adhesion. A signal transduction pathway has been rewired, partly because of polymorphisms in a transcription factor.

Gene functional trade-offs and the evolution of pleiotropy, pp. 1389-1409 Frdric Guillaume and Sarah P. Otto Pleiotropythe property of genes affecting multiple features of an organismis often considered to be an unavoidable by-product of a gene's evolutionary history. These authors explored how the pleiotropic degree of a gene may evolve, providing clues to why pleiotropy varies among genes. They found two common outcomes of the evolution of multifunctional genes: increased pleiotropy of genes more highly expressed, and specialization of all genes on the trait most important to fitness.

Receptors and other signaling proteins required for serotonin control of locomotion in Caenorhabditis elegans, pp. 1359-1371 Gliz Grel, Megan A. Gustafson, Judy S. Pepper, H. Robert Horvitz, and Michael R. Koelle This article offers insight into the mechanism of signaling by serotonin, a neurotransmitter involved in mood disorders in humans. The authors carried out screens for C. elegans mutants that fail to respond properly to this neurotransmitter, which worms use to control locomotion. They identified mutations in more than eight genes required for serotonin signaling. Two encode serotonin receptors, while the others encode proteins that in some cases are implicated for the first time in serotonin signaling by this work. There are similar human proteins that may mediate serotonin signaling in our brains. The two C. elegans serotonin receptors appear to act in parallel in different cells to coordinate behavioral responses to serotonin.

Long-term and short-term evolutionary impacts of transposable elements on Drosophila, pp. 1411-1432 Yuh Chwen G. Lee and Charles H. Langley Transposable elements are ubiquitous genomic parasites. Even though they are primarily vertically inherited as part of the genome, their interactions with the host are often likened to the coevolution of host genes and nongenomic, horizontally transferred pathogens. Here Lee and Langley show that genes involved in the interaction with transposable elements indeed show strong signals of positive selection similar to those of immunity genes in Drosophila, but with a fundamentally different mechanism from that of host-pathogen coevolution.

Unusual and typical features of a novel restorer-of-fertility gene of sugar beet (Beta vulgaris L.), pp. 1347-1358 Hiroaki Matsuhira, Hiroyo Kagami, Masayuki Kurata, Kazuyoshi Kitazaki, Muneyuki Matsunaga, Yuko Hamaguchi, Eiki Hagihara, Minoru Ueda, Michiyo Harada, Aki Muramatsu, Rika Yui-Kurino, Kazunori Taguchi, Hideto Tamagake, Tetsuo Mikami, and Tomohiko Kubo Plant pollen production is often impaired by incompatibility between the mitochondria and nucleus. A nuclear gene termed Rf can cancel this cytoplasmic male sterility. These authors report that sugar beet Rf encodes a metalloprotease-like gene, in contrast to other Rfs which encode proteins supposed to bind RNA. Interestingly, the sugar beet Rf locus exhibits the gene clustering often seen in plant Rf loci, suggesting a common evolutionary mechanism regardless of the Rf gene products.

More here:
Genetics Society of America's Genetics journal highlights for December 2012

Recommendation and review posted by Bethany Smith

CHARLEROI, Belgium--(BUSINESS WIRE)--

During the inauguration of its new building, the Belgian Biotech Company Delphi Genetics SA announced that the first antibiotic-free DNA vaccine using the Staby technology was efficiently tested in vivo. Together with academic and Biotech key-players, Delphi Genetics is participating to the DNAVAC project funded by the Walloon Region (BioWin project). The aim of the project is to develop and produce antibiotic-free DNA vaccines targeting veterinary diseases. As a model, the consortium developed a DNA vaccine against the Aujezsky virus the causative agent of pseudo-rabies.

This virus was selected as it causes systematically an acute and lethal disease in susceptible species, thereby providing an excellent model to test the efficacy of a vaccine candidate. The results of the challenge performed by Dr Anca Reschner are very clear: all vaccinated animals using the Staby vectors were resistant to the lethal Aujeszky virus. said Prof. Alain Vanderplasschen from the University of Lige (Immunology-Vaccinology).

Cdric Szpirer PhD, Delphi Genetics co-Founder and CEO, explained: This is the first real DNA vaccine produced using the Staby technology. Several DNA vectors have been made in the past to generate production of antibodies, but this is the first time that in vivo tests were performed in order to evaluate efficiency against a disease. All production steps of the vaccine were performed efficiently avoiding completely the use of antibiotic-resistance genes as recommended by regulatory authorities (FDA, USDA, EMA). These results validate the use of Staby outside the field of protein production.

Indeed, a few weeks ago, on October, 8 Delphi Genetics announced a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress technology to produce proteins in the areas of human and animal health. The same technology was licensed previously to Sanofi-Pasteur (2009) and GSK (2010) for production of proteins used in human vaccines.

As announced on January, 30, 2012, the DNAVAC project involves a consortium including Eurogentec SA, another Belgian Biotech company (part of Kaneka) in charge of large scale DNA production and purification, and two universities: the Catholic University of Louvain in charge of pharmaceutical and toxicity studies associated with the project and the University of Lige in charge of vaccinology and veterinary aspects.

About Delphi Genetics SA

Founded at the end of 2001, Delphi Genetics SA develops technologies for genetic engineering and protein expression using unique expertise in the domain of plasmid stabilisation systems. Since 2004, Delphi Genetics has been marketing innovative kits and services for researchers. Some of these kits contain the Staby technology that has since been licensed for industrial applications (see above). Indeed, the Staby technology can be applied to any industrial DNA or protein production process that involves bacterial fermentation. Delphi Genetics is involved in several research projects including adaptation of the technology to yeast and mammalian cells.

http://www.delphigenetics.com

Read more:
The Staby® Technology from Delphi Genetics Efficiently Applied To DNA-Vaccine

Recommendation and review posted by Bethany Smith

NEW YORK (AP) Shares of Myriad Genetics Inc. declined Monday after the U.S. Supreme Court agreed to hear a challenge to the practice of issuing patents on human genes.

THE SPARK: On Friday the Supreme Court said it will decide on a case on the patenting of genes. Myriad holds two genetic patents related to its BRACAnalysis test, which detects genetic mutations that are linked to increased risks of breast and ovarian cancer. The U.S. Patent and Trademark Office has been issuing DNA patents for almost 30 years, but the American Civil Liberties Union has challenged the practice.

THE BIG PICTURE: The Salt Lake City reported $405.5 million in revenue from BRACAnalysis testing in the fiscal year ended June 3, or 86 percent of its total revenue. Myriad and analysts say the test is protected by other patents, so Myriad would not immediately lose patent protection on the test if the Supreme Court rules that human genes can't be patented.

The ACLU and other groups have argued that the government shouldn't award patents on genes and that the patents prevent other groups for doing research. In March 2010 a New York district court ruled against Myriad, but the U.S. Court of Appeals for the Federal Circuit has ruled in Myriad's favor twice, most recently in August.

In March 2012 the Supreme Court threw out genetic patents held by Prometheus Laboratories that covered a test designed to help doctors set drug doses for autoimmune diseases like Crohn's disease. Some investors felt that decision was bad news for Myriad, but analysts have said the patents are not very similar to those held by Myriad.

THE ANALYSIS: Jefferies & Co. analyst Jon Wood said in a note Monday Myriad's patents should ultimately be upheld, and no matter what the court rules, the company's other patents should keep generic competition for BRACAnalysis from reaching the market until fiscal 2018. He rates the stock "Buy," with a $33 price target.

SHARE ACTION: Shares of Myriad Genetics lost 73 cents, or 2.5 percent, to $27.99 in midday trading. Earlier the stock fell as much as 6.4 percent. Myriad shares are up 37 percent in 2012.

Go here to see the original:
Myriad Genetics slips on Supreme Court review

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Dec 3, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that it has been designated as the Expertise Partner to the 2nd Annual Cancer Genome Summit being held December 4-6, 2012 at the Revere Hotel Boston Common in Boston, Massachusetts.Dr. Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO and president of Atossa Genetics, will present on Thursday, December 6th, 2012, during the morning session.

Dr. Quay's presentation will focus on breast cancer prevention through the diagnosis and treatment of the abnormal cells that are the precursors of cancer, so-called reversible hyperplastic intraductal lesions. His presentation will include:

"Using Atossa Genetics' patented, FDA-cleared medical devices and our patented high-complexity laboratory developed tests to diagnose reversible, pre-cancerous breast changes and then treat them locally with intraductal therapy provides a platform that has the potential to realize our goal of preventing breast cancer," stated Dr. Steven Quay, MD, PhD, FCAP. "We look forward to identifying forward-looking pharma and biotech companies with novel treatment formulations to partner in this new paradigm for breast health, intraductal treatment of pre-cancerous lesions."

The Cancer Genome Summit is the only meeting that brings together thought leaders from pharmaceutical companies, academia and the clinic, to discuss harnessing the cancer genome to revolutionize drug development programs and patient treatment choices. The presentations will include the latest clinical data. Sharing these insights holds the key to understanding how genes cause cancer and how diagnostics and treatments can be improved. This year's meeting will show attendees how to identify new drug targets, combat resistance mechanisms, streamline clinical trials, and improve clinical management. More information about the meeting may be found at Cancer Genome Summit.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission.All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Read the original:
Atossa Genetics, Inc. Designated Expertise Partner to Cancer Genome Summit

Recommendation and review posted by Bethany Smith

Last month, a large team led by researchers at Boston hospitals reported a surprising result: a common variation in a gene was associated with being an early bird, and with the time of day people died.

Given how many things affect when we wake upnot to mention all the experiences accumulated over a lifetime that contribute to how and when we dieit seems a little crazy that a single gene could be meaningfully linked to those complicated traits.

But over the years, it has become increasingly clear that our bodies run on their own clocks, and that health is inextricably linked to those rhythms. Shift workers forced to adopt a schedule wildly out of rhythm with a typical day raise their risk of obesity and diabetes. Heart attacks have a propensity to strike in the morning and asthma attacks at night. A growing body of evidence suggests giving cancer drugs at specific times of day can make a therapys side effects less harsh.

The scientists who published the new findings in the Annals of Neurology said the research needs to be repeated in a larger group of people to see whether it holds up. They acknowledged that a complex trait such as being a night owl or dying at dusk rather than mid-day would likely have many contributions, not just one gene. But, given the obvious importance of our bodys natural rhythms, they and others argue, it is important to try and unravel the biology of the clock.

What youd like to do is youd like to see if theres some predictive value here, said Dr. Clifford Saper, chief of neurology at Beth Israel Deaconess Medical Center, and a coauthor. Could you predict who would be able to adjust to a job that requires that you start at 6 a.m.? ... Would you be able to pick your job based on knowing your genetic predisposition.

Researchers not involved in the study said it was a fascinating result, but just a first step in teasing out how the human body clock works, and what effect perturbing the clock can have.

The very significant association in their discovery data is on the one hand reassuring, but also suggests a massive effectreally atypical for complex traits like this, Jeffrey Barrett, a group leader at the Wellcome Trust Sanger Institute in England, wrote in an e-mail.

Dr. Louis Ptacek, a professor of neurology at the University of California, San Francisco, said that the study was interesting but that because the sleep-wake cycle is influenced by so many things, including things that range from genes to jobs, he has focused in his research on a different approach: studying true outliers, whose sleep schedules are radically shifted.

Studying rare, more extreme diseases to gain insight into more common conditions has become common in medicine. The connection between LDL cholesterol and heart disease, for example, was partly revealed by research into a rare genetic disorder that caused people to have heart attacks when they were young.

You and I have the biological tendency to wake up at a certain time, but you override that all the time because you have a deadline or you take coffee in the morning, or you have a glass of wine with dinner, Ptacek said. So instead of trying to unravel all the different reasons that people might tend to wake up a bit earlier or later, Ptacek has spent much of his career studying people who naturally wake up in the wee hours of the morning and go to bed before prime time.

Continued here:
Researchers identify a gene that may predict what time of day people die

Recommendation and review posted by Bethany Smith

GULF SHORES, Ala., Dec. 4, 2012 /PRNewswire/ --More than 75 percent of amyotrophic lateral sclerosis (ALS) patients who received neural reprogrammed stem cell therapy have shown a positive response to the procedure. The groundbreaking technique was introduced to the United States this year by Precision StemCell (http://www.precisionstemcell.com), an outpatient imaging and image-guided treatment facility located in Gulf Shores, Ala.

The procedure is performed by Dr. Jason R. Williams, a board-certified radiologist with extensive training in image-guided procedures. Under his care, 14 out of 18 patients diagnosed with ALS, also known as Lou Gehrig's disease, have shown signs of recovery.

"The improvements are mild, with patients reporting improved movement, breathing and speech, but we still have a long way to go," Dr. Williams stated. "Only time will tell how this therapy will affect the patients' long-term prognosis."

In Precision StemCell's neural reprogrammed stem cell therapy, fat-derived stem cells are injected into the spine of the patient. Dr. Williams uses a drug called selegeline, which has been shown to be a pre-inducer of adipose-derived stem cells into neural-like cells. Dr. Williams contends that the therapy is probably one of the largest advances seen in ALS therapy. "Before we started this therapy, I would have been happy just to see the progression of the disease halted, but to see some actual improvement, that was just shocking," he said

The first patient treated with the technique was Frank Orgel who continues to see improvement since his first treatment seven months ago. Eight years ago, Orgel's quality of life had declined to the point that he could not move his left arm or leg, walk or even stand on his own. The therapy has allowed Orgel to stand without assistance, and he continues to work with a physical therapist to regain the ability to walk. Another patient, Dexter Johnson, previously walked with a cane. After the treatment, Johnson has been able to walk without his cane for the majority of the time and he has been able to walk at a much faster pace.

The Precision StemCell center focuses on advanced imaging techniques, which include a 3T Open MRI, a low-dose 64-Slice CT Scanner, ultrasound and fluoroscopy, also known as real-time x-ray. The center is headed by Dr. Williams, who specializes in image-guided procedures, had already been performing magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and fluoroscopy-guided stem cell injections for joint and orthopedic conditions.

In addition to their current work on advanced stem cell harvesting and processing with image-guided stem cell injections, Precision StemCell staff are planning to conduct further research so as to develop even more advanced techniques such as adding gene therapy to the current neural reprogramming platform. "Our therapy techniques not only hold promise for ALS patients, but also for people with other neural-related conditions such as Parkinson's and spinal cord injuries," said Dr. Williams. "There are several candidate genes that we plan to add to the adipose-derived stem cells and study in the mouse model. Though we are happy with our initial progress, our goal is to develop an effective cure."

About Precision StemCell

Located in Gulf Shores, Alabama, Precision StemCell conducts stem cell procedures using advanced imaging techniques, which include an Open 3T MRI, a low-dose 64-Slice CT scanner, ultrasound, and real time x-ray (fluoroscopy). Headed by Jason Williams, MD, a board-certified radiologist with extensive training in image-guided procedures, the facility performs advanced stem cell harvesting and processing with image-guided stem cell injections.

Contact:

Read more here:
Precision StemCell's Neural Reprogrammed Stem Cell Therapy Yields Better-Than-Expected Results for ALS Patients

Recommendation and review posted by simmons

Personalized Medicine with Dr. Liggett
The University of Florida now has a new research doctor on its campus, Dr. Stephen Liggett. His research focuses on using "personalized medicine" to diagnose and treat patients. It is a process that takes an individual #39;s genetic makeup to create a personalized healing process for a given disease. I reported on, wrote, and edited this story. This story was for CTTV #39;s Spotlight Tampa.From:Caroline MetellViews:1 0ratingsTime:03:50More inNews Politics

Read the original here:
Personalized Medicine with Dr. Liggett - Video

Recommendation and review posted by sam

Dr. Marko-Varga Talks Personalized Medicine
Dr. Gyorgy Marko-Varga, President of the European Proteomics Association and co-chair of the Chromosome-centric Human Proteome Project (C-HPP) talks about the future of proteomics and personalized medicine.From:ThermoScientificViews:7 0ratingsTime:02:30More inScience Technology

Visit link:
Dr. Marko-Varga Talks Personalized Medicine - Video

Recommendation and review posted by sam

Presentation- Multiple Myeloma Research Foundation/Genospace 3928
The Multiple Myeloma Research Foundation (MMRF) and its Personalized Medicine Initiative Consortium launched the CoMMpass Study to map 1000 myeloma genomes. Genospace provides IT services and bioinformatics expertise including computational workflows and networked communities on a single platform. The MMRF-Genospace partnership unifies comprehensive longitudinal clinical and genomic data with expert bioinformatics tools and social networking to drive data access and knowledge building insights to patients, collaborators, and the public. The project #39;s common goal is to increase access, promote discovery, and expedite development of drugs, diagnostics, and clinical trials. Its collaborative model shortens the timelines to access, analyze, share, and translate important findings into the clinic. Presented by: Carolyn Hoban, DSc Director of Translational Research, Multiple Myeloma Research Foundation Mick Correll Co-founder and COO, GenospaceFrom:FasterCuresViews:4 0ratingsTime:25:26More inNonprofits Activism

View original post here:
Presentation- Multiple Myeloma Research Foundation/Genospace 3928 - Video

Recommendation and review posted by sam